Today’s announcement builds on a previous announcement of more than 40% off the Eliquis list price, a direct-to-consumer program that began earlier this month.

Panelists discuss how bimekizumab demonstrated significant improvements in pain scores (from baseline levels around 60/100) and fatigue measures, with meaningful percentages of patients achieving ...

FDA rejects Rexulti's approval for PTSD treatment, citing insufficient evidence of effectiveness in combination with sertraline. Otsuka and Lundbeck announced they are planning next steps.

Robert Gamble, CEO of RxBenefits, shares how Illuminate Rx does specialty, plus the areas they will continue to innovate on.

The FDA letter requested that a technical information update be included in the Chemistry Manufacturing and Controls (CMC) ...

Research shows older adults had 4.45 million skin cancer cases in 2021. Basal cell carcinoma is expected to double by 2050 worldwide.

Judi Health redefines health benefit management with a $400 million funding boost, enhancing transparency and efficiency for employers and health plans.

Investigators have identified the lowest dose of the immunosuppressive ATG needed to preserve beta cells in newly diagnosed children with Type 1 diabetes with the lowest side effects.

Yael Bensoussan, M.D., director of the University of South Florida Health Voice Center, discusses menopause-related voice ...

A groundbreaking NLP algorithm accurately identifies precancerous gastric and esophageal conditions from EHRs, enhancing early detection and personalized patient care.

Carbapenemase-producing Enterobacterales (CRE) surge in the U.S., with New Delhi metallo-β-lactamase (NDM) becoming a major public health threat.

The complete response letter was issued by the FDA during a routine inspection of a third-party fill-finish facility, not because of an issue with apitegromab.